Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mind Medicine (MindMed) Inc. MNMD
$3.05
-$0.04 (-1.27%)
На 18:04, 12 мая 2023
+63.93%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
124657635.00000000
-
week52high
19.95
-
week52low
2.12
-
Revenue
0
-
P/E TTM
-2
-
Beta
2.15304700
-
EPS
-1.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 04 янв 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Barrow Robert | D | 247232 | 3861 | 21 дек 2022 г. |
| Karlin Dan | D | 264082 | 1211 | 21 дек 2022 г. |
| Karlin Dan | D | 265293 | 644 | 27 окт 2022 г. |
| Karlin Dan | D | 265937 | 541 | 25 окт 2022 г. |
| Barrow Robert | D | 251093 | 1207 | 25 окт 2022 г. |
| Barrow Robert | D | 252300 | 1220 | 18 окт 2022 г. |
| Karlin Dan | D | 266478 | 640 | 27 сент 2022 г. |
| Karlin Dan | D | 267118 | 565 | 26 сент 2022 г. |
| Barrow Robert | D | 253520 | 1264 | 26 сент 2022 г. |
| Barrow Robert | D | 254784 | 1350 | 16 сент 2022 г. |
Новостная лента
The 7 Most Promising Psychedelic Stocks to Buy in February
InvestorPlace
05 февр 2023 г. в 14:30
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Psychedelic Sunday: Competitive Strategies
Seeking Alpha
15 янв 2023 г. в 11:45
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
Scrutinizing Psychedelic Stocks
Seeking Alpha
08 янв 2023 г. в 11:30
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
Zacks Investment Research
06 дек 2022 г. в 21:49
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
MindMed price target lowered by Canaccord analysts after Phase 2a US clinical trial shelved
Proactive Investors
21 ноя 2022 г. в 11:55
Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) Inc has earned a repeat ‘Speculative Buy' rating with a lowered price target of US$18 from US$22 per share from Canaccord Genuity (TSX:CF, LSE:CF) analysts following the release of its third-quarter results last week. The biotechnology company's shares are currently trading at about US$2.60 per share.